rs140413151
Positions:
Variant summary
Our verdict is Benign. Variant got -12 ACMG points: 1P and 13B. PP3BP4_StrongBP6BS1BS2
The NM_005327.7(HADH):c.643C>A(p.Pro215Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00302 in 1,603,218 control chromosomes in the GnomAD database, including 15 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0025 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0031 ( 14 hom. )
Consequence
HADH
NM_005327.7 missense
NM_005327.7 missense
Scores
11
6
2
Clinical Significance
Conservation
PhyloP100: 6.17
Genes affected
HADH (HGNC:4799): (hydroxyacyl-CoA dehydrogenase) This gene is a member of the 3-hydroxyacyl-CoA dehydrogenase gene family. The encoded protein functions in the mitochondrial matrix to catalyze the oxidation of straight-chain 3-hydroxyacyl-CoAs as part of the beta-oxidation pathway. Its enzymatic activity is highest with medium-chain-length fatty acids. Mutations in this gene cause one form of familial hyperinsulinemic hypoglycemia. The human genome contains a related pseudogene of this gene on chromosome 15. [provided by RefSeq, May 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -12 ACMG points.
PP3
Multiple lines of computational evidence support a deleterious effect 8: BayesDel_addAF, BayesDel_noAF, Cadd, Eigen, M_CAP, MutationAssessor, PROVEAN, REVEL [when max_spliceai, FATHMM_MKL, MetaRNN, MutationTaster was below the threshold]
BP4
Computational evidence support a benign effect (MetaRNN=0.05675757).
BP6
Variant 4-108027694-C-A is Benign according to our data. Variant chr4-108027694-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 549514.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=4, Uncertain_significance=4, Uncertain_risk_allele=1}.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00246 (374/152220) while in subpopulation NFE AF= 0.00372 (253/68004). AF 95% confidence interval is 0.00334. There are 1 homozygotes in gnomad4. There are 173 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAdExome4 at 14 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HADH | NM_005327.7 | c.643C>A | p.Pro215Thr | missense_variant | 6/8 | ENST00000309522.8 | NP_005318.6 | |
HADH | NM_001184705.4 | c.643C>A | p.Pro215Thr | missense_variant | 6/9 | NP_001171634.3 | ||
HADH | NM_001331027.2 | c.655C>A | p.Pro219Thr | missense_variant | 6/8 | NP_001317956.2 | ||
HADH | XR_007096395.1 | n.687C>A | non_coding_transcript_exon_variant | 6/8 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HADH | ENST00000309522.8 | c.643C>A | p.Pro215Thr | missense_variant | 6/8 | 1 | NM_005327.7 | ENSP00000312288.4 |
Frequencies
GnomAD3 genomes AF: 0.00246 AC: 374AN: 152102Hom.: 1 Cov.: 32
GnomAD3 genomes
AF:
AC:
374
AN:
152102
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00183 AC: 459AN: 251450Hom.: 2 AF XY: 0.00170 AC XY: 231AN XY: 135898
GnomAD3 exomes
AF:
AC:
459
AN:
251450
Hom.:
AF XY:
AC XY:
231
AN XY:
135898
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00308 AC: 4465AN: 1450998Hom.: 14 Cov.: 27 AF XY: 0.00298 AC XY: 2153AN XY: 722762
GnomAD4 exome
AF:
AC:
4465
AN:
1450998
Hom.:
Cov.:
27
AF XY:
AC XY:
2153
AN XY:
722762
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00246 AC: 374AN: 152220Hom.: 1 Cov.: 32 AF XY: 0.00232 AC XY: 173AN XY: 74422
GnomAD4 genome
AF:
AC:
374
AN:
152220
Hom.:
Cov.:
32
AF XY:
AC XY:
173
AN XY:
74422
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
22
ALSPAC
AF:
AC:
14
ESP6500AA
AF:
AC:
4
ESP6500EA
AF:
AC:
31
ExAC
AF:
AC:
203
Asia WGS
AF:
AC:
3
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:5Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Deficiency of 3-hydroxyacyl-CoA dehydrogenase Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not provided Benign:2
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | HADH: BS2 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 28, 2021 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 32876354, 25007923) - |
Deficiency of 3-hydroxyacyl-CoA dehydrogenase;C1864948:Hyperinsulinemic hypoglycemia, familial, 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Monogenic diabetes Uncertain:1
Uncertain significance, criteria provided, single submitter | research | Personalized Diabetes Medicine Program, University of Maryland School of Medicine | Mar 31, 2017 | ACMG Criteria:PP3 (11 predictors), BS2 (18 cases and 25 controls in type2diabetesgenetics.org for AD monogenic diabetes; two homozygotes in ExAC) - |
Hyperinsulinemic hypoglycemia, familial, 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 03, 2021 | This sequence change does not appear to have been previously described in individuals with HADH-related disorders. This sequence change has been described in the gnomAD database with a frequency of 0.014% (dbSNP rs140413151). The p.Pro215Thr change affects a highly conserved amino acid residue located in a domain of the HADH protein that is not known to be functional. The p.Pro215Thr substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidence and the lack of functional studies, the clinical significance of the p.Pro215Thr change remains unknown at this time. - |
HADH-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 11, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Hyperinsulinemic hypoglycemia Other:1
Uncertain risk allele, criteria provided, single submitter | research | Clinical Genomics, Uppaluri K&H Personalized Medicine Clinic | - | Potent mutations in HADH gene are associated with congenital hyperinsulinism, which leads to recurrent hypoglycemia. The condition is exacerbated by stress, fasting or excessive dietary protein. May respond well to diazoxide. However, the role of this particular variant rs140413151 in congenital hyperinsulinism is yet to be ascertained. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
.;.;D;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T;T
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
.;M;M;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;.;D;.;D;.
REVEL
Pathogenic
Sift
Uncertain
.;.;D;.;D;.
Sift4G
Uncertain
.;D;D;.;.;D
Polyphen
1.0
.;.;D;.;.;.
Vest4
0.83, 0.84, 0.84
MVP
MPC
0.89
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at